Latest RMD News

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Resmed Inc. reported a robust 10% revenue increase and a 19% rise in operating profit for fiscal 2025, alongside a 13% dividend hike, driven by strong demand for sleep and breathing health devices and growth in digital health software.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payable to ASX-listed CDI holders, impacting the Australian dollar equivalent of the payout.

ResMed Inc. has updated the foreign exchange rate impacting its upcoming dividend payment to Australian CDI holders, reflecting currency volatility and tax treaty benefits.

ResMed Inc. reported robust financial results for the quarter ended December 31, 2024, with a 10% increase in net revenue and a 65% jump in net income, driven by strong demand across its Sleep and Breathing Health and Residential Care Software segments.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.